ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) — Femasys Inc. FEMY, a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including two lead revolutionary late-clinical stage product candidates and FDA-cleared, innovative diagnostic products, today announced the achievement of First-Patient-In for…Read More
Femasys Announces FirstPatientIn for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control Femasys NASDAQFEMY
